Aceragen, Inc.
ACGN
NASDAQ Capital Market0.38
USD
+0.00
- -
Aceragen, Inc.
ACGN
(NASDAQ Capital Market)
Recent
price
0.38
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Aceragen, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel drug candidates addressing rare pulmonary and rheumatic diseases. The company’s main products include ACG-701, a proprietary oral formulation of sodium fusidate under development for acute pulmonary exacerbations associated with cystic fibrosis and melioidosis, a life-threatening infectious disease; and ACG-801, a recombinant human acid ceramidase intended as an enzyme replacement therapy for Farber disease, a rare lysosomal storage disorder. Aceragen's pipeline emphasizes rare disease indications characterized by small, well-defined patient populations with significant unmet medical needs. The company operates primarily in the United States but targets global rare disease markets. Founded in 1989 and headquartered in Exton, Pennsylvania, Aceragen emerged from the former biotechnology company Idera Pharmaceuticals after a strategic merger and rebranding in early 2023. Recent major changes include the acquisition of Aceragen by Idera Pharmaceuticals in 2022, completed as a stock-for-stock transaction to combine resources for advancing the rare disease pipeline. Following this, Idera Pharmaceuticals changed its name to Aceragen, Inc. in January 2023, signaling a strategic shift to focus on late-stage rare disease therapeutics. Aceragen has secured multiple designations for ACG-701 including FDA Fast Track, Orphan Drug, and Qualified Infectious Disease Product status, supporting accelerated development. The company entered into a development partnership with the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA) providing approximately $50 million to explore ACG-701 as a medical countermeasure for melioidosis. However, Aceragen has faced operational challenges such as clinical hold issues on the ACG-801 Farber disease program due to manufacturing concerns and has undertaken corporate restructuring including workforce reductions reported in 2025 to streamline operations. Aceragen intends to voluntarily terminate its Nasdaq Capital Market listing subject to shareholder approval as part of broader strategic realignment. Overall, Aceragen, Inc. leverages its proprietary drug candidates targeting rare genetic and metabolic disorders, with a comprehensive focus on pulmonary, infectious, and rheumatic rare diseases, driven by clinical-stage development and strategic partnerships to address critical unmet medical needs in small patient populations.
MoonFox Analysis | "ACGN Merch Economy" Surge and the Breakthrough of the "Dimension Wall" in ACGN Consumption
Aceragen, Inc. to Delist from The Nasdaq Stock Market